Loading
A phase 1/2 trial of Tislelizumab in advanced solid tumours, run by FindCure Biosciences (ZhongShan) Co., Ltd., now recruiting.
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT06499350 by FindCure Biosciences (ZhongShan) Co., Ltd., with 33 participants planned, started 2024-11-13 and due to reach its primary completion in 2026-12-01. Interventions recorded: FC084CSA+Tislelizumab combination (dose escalation) and RP2D of FC084CSA+Tislelizumab combination (dose expansion).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tislelizumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/